This clinical trial focuses on patients with Multiple Myeloma who have experienced disease progression or relapse after initial treatment. The study compares two treatment approaches: allogeneic stem cell transplantation (using stem cells from a donor) versus conventional therapy. The main purpose is to determine which treatment leads to better survival outcomes over a 5-year period.
The treatment options in this study include several medications that work in different ways to fight the disease. These include lenalidomide, pomalidomide, and dexamethasone, which help control the immune system. Other medications used are bortezomib, carfilzomib, and ixazomib citrate, which work by blocking certain cell processes. The study also uses targeted treatments called daratumumab, isatuximab, and elotuzumab, which are antibodies that help the immune system identify and attack cancer cells.
The study will track how well patients respond to treatment by measuring survival time, checking if the disease comes back, monitoring side effects, and assessing quality of life. Patients will be followed for several years to understand the long-term effects of both treatment approaches. The study specifically looks at the development of complications after stem cell transplantation, including a condition called graft-versus-host disease, where the donated cells attack the patient’s body.
Germany 
